Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. - Wikidata - awgldk - TriplyDB

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

http://www.wikidata.org/entity/Q37022726

about

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.Canagliflozin: a novel treatment option for type 2 diabetes.Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?Empagliflozin in the treatment of type 2 diabetes: evidence to date Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Inhibition of the intestinal sodium-coupled glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood glucose levels in mice and humans.Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.SGLT1 activity in lung alveolar cells of diabetic rats modulates airway surface liquid glucose concentration and bacterial proliferation.Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.Canagliflozin.Circulating SerpinB1 levels and clinical features in patients with type 2 diabetes.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.

P2860

Q26767263-B8522BB4-17F3-48AF-A254-E38C025DF700 Q26777529-BC67B590-837D-4DAE-8730-45487E387D25 Q26827362-4AFB1305-052E-4853-8BAD-994FE700F6C2 Q27010669-5BEFACC8-1BAC-48AE-AFFE-5BB3A7AE795C Q28076978-08B8DA58-942F-4C0B-B692-907953F98CEA Q33356608-8B19DA44-C7F2-463E-94AA-C6950281AB91 Q33567077-A5DF0AE0-2091-4310-BC8D-F906056BDF81 Q33759610-CB3F31B0-6B55-493B-8E59-1E1B8C65933A Q33837017-51DC82A7-2AB1-4B73-8308-0D2799DC6B07 Q33845734-B6FC31B2-4592-478D-AEEB-09D1A6EA8EC2 Q34161881-CA6F3DAB-6D61-415A-BBB6-53CE5BCF511D Q34198692-DD87CA5F-3394-44AF-9DD7-4746AC17826E Q34264365-65E57679-2891-450D-8B6E-6A5D5B34E92C Q34388544-7A8BE4AF-1A53-4464-84DA-E30892A77F87 Q34486820-EE9CDB4D-AB3D-42F7-B1F6-5E85E9F01336 Q34502358-AEDD9D63-51D9-46A0-BD39-2007D1F81206 Q34646948-E7DB5FAF-C0DA-4A4F-8427-516A92DE344A Q34973750-FB13508E-F58E-4088-AE2D-907566A8B318 Q35215364-C76E53FA-379A-4FE2-956C-061C9DA7D2E1 Q35830021-AE296344-631D-4FAB-A72F-1B27AB1ADDEC Q36022710-045F3EEC-5F2E-4AFF-BC7C-F33F74A2C7F0 Q36207940-B2F50BF9-ABE3-4F47-B896-35B08E393AA7 Q36257199-265FDE31-EA2B-4D37-83B1-CE7D3E3D302F Q36257565-9C141F1E-EEA6-4076-8BC8-9466E7CA86F4 Q36277977-3C936D5B-B6F2-4F62-9CAC-63A48BA40F35 Q36431654-CE0FC2D9-2BF1-4DAD-91F5-D867E3D3D51D Q36605834-FDBB6618-C014-47DF-BF2F-12575736AB0E Q36765350-368B4B4D-819B-471D-A1B3-DC8DCD6B0276 Q36989681-0D6844FB-725A-4814-83E4-422E27D7EF2D Q37383648-49724010-FAAE-472A-B025-9A1C755E12C6 Q37454408-89C0541A-0DA2-4A47-B71F-6FBF62C6567A Q37509313-1C273D81-A69D-4913-877F-4B5ED9236240 Q37524302-D311CB74-699D-454B-B7C2-71FCD12972F5 Q37588842-7BDF68A8-445A-4D00-9826-2C30FE7C29CF Q37588847-F114AFA9-2FA4-4A45-A9A9-11B014CE760A Q37589626-01F17B83-D256-43A0-84D4-8BB01CBB5AEE Q37672448-B4D73F8B-4F0A-45C6-B7BC-81AD9DDA0687 Q37692849-6C8342CC-B05B-47A9-9AF0-F431F50C32CE Q38130748-90B7579E-D2AB-482C-BA02-281EC55390A8 Q38164682-CE282E8A-7A60-4623-BDD8-B27F94ED274F

P2860

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

http://www.wikidata.org/entity/Q37022726

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Canagliflozin lowers postprand ...... zed, placebo-controlled study.

@en

Canagliflozin lowers postprand ...... zed, placebo-controlled study.

@nl

type

label

Canagliflozin lowers postprand ...... zed, placebo-controlled study.

@en

Canagliflozin lowers postprand ...... zed, placebo-controlled study.

@nl

prefLabel

Canagliflozin lowers postprand ...... zed, placebo-controlled study.

@en

Canagliflozin lowers postprand ...... zed, placebo-controlled study.

@nl

P1433

Q37022726-C7E240CC-6BF0-4C73-973A-9C25402C5D88

P1476

Q37022726-1EECF8D9-2EF6-44AB-8D99-E61F6E090D0B

P2093

Q37022726-200700D0-CEB8-4639-BAB4-B2BA8E6DD7BA

Q37022726-206C68AC-AA36-462D-BF0D-A15806927331

Q37022726-437AAF95-F900-4538-8EFF-E6CE9C00628E

Q37022726-81913100-3051-4997-8EC5-71AA17F23DB7

Q37022726-84AE265C-3A10-4ADB-BF67-FBFD935B12F3

Q37022726-9732F2BB-D98C-4011-9C1A-C1CCF7A92794

Q37022726-A6E1D2FA-ABB1-40B0-957C-ACD4008B7E9C

Q37022726-F22311AB-CCB0-4EB8-BB2D-AE0D3E08A35B

Q37022726-F7479DF7-B7D7-47A4-949F-1AB293B29A93

P2860

Q37022726-054DC999-D7C8-4A7D-AE54-118336E07002

Q37022726-07CCD7EB-57BA-4F8A-B73A-610BB6763771

Q37022726-15419806-0F2D-4F99-B40F-E50D4049B47C

Q37022726-287EBC80-FC2A-467D-8018-B41E928A9588

Q37022726-3492F297-A5D1-4B56-B136-F339CB11F1BE

Q37022726-459F0D75-9F0E-428D-AA59-0EE9072AC87A

Q37022726-551A67B9-939B-4FC5-9FB4-069C3E0BEB31

Q37022726-6B682672-7BD5-4A2C-9E5B-5B0EFD02536F

Q37022726-78D5E91A-3B76-42B4-A72F-766E66F74FA3

Q37022726-79DB5511-192D-4BDA-AEBD-1B83EE802A16

P304

Q37022726-C8C8C3E9-BB32-495A-8714-1BCC978DB102

P31

Q37022726-C2AF09AD-7098-4CCD-B5FE-9077D141ADF0

P356

Q37022726-13BDE0B6-5301-4260-BBF8-A13923FE212E

P407

Q37022726-F94DAC20-8D17-4568-8ED7-4D6973908164

P433

Q37022726-CA966677-0187-467B-890A-8ABD7DF671A3

P478

Q37022726-92531829-4045-41B4-8A4C-C1825023063E

P577

Q37022726-7737C4BB-8DF9-41E7-A487-61F1C34B7186

P5875

Q37022726-007D0F26-26F1-4CAE-B555-112DA109CED0

P698

Q37022726-991C2EB3-5ED5-4484-A20B-2A54C1FDFBBB

P921

Q37022726-1CD951B9-4F70-47D4-9CE1-2821BACEEFB4

Q37022726-64851AB8-E8CC-4E77-BE27-29505497ECED

Q37022726-87DE8FC1-5CB6-4C3B-9D5F-2A70347446D4

Q37022726-B98A608E-8F59-4103-B8D7-CCD312204D14

Q37022726-D4A118E2-4A4C-46B8-A0A5-6D4A37CB5D9E

Q37022726-adcbab16-5764-4059-9f88-63b6b394f797

P932

Q37022726-B43A9BEB-019D-4527-978D-FDDA33D89D75

P356

P1433

P1476

Canagliflozin lowers postprand ...... zed, placebo-controlled study.

@en

P2093

Atalanta Ghosh

http://www.w3.org/2001/XMLSchema#string

David Polidori

http://www.w3.org/2001/XMLSchema#string

Kristin Farrell

http://www.w3.org/2001/XMLSchema#string

Nicole Vaccaro

http://www.w3.org/2001/XMLSchema#string

Paul Rothenberg

http://www.w3.org/2001/XMLSchema#string

Robert R Henry

http://www.w3.org/2001/XMLSchema#string

Sue Sha

http://www.w3.org/2001/XMLSchema#string

Sunder Mudaliar

http://www.w3.org/2001/XMLSchema#string

Theodore P Ciaraldi

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Inhibition of gastric emptying and drug absorption by narcotic analgesics

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion

Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.

Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells.

Biology of human sodium glucose transporters.

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

P304

2154-2161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC12-2391

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235629302

http://www.w3.org/2001/XMLSchema#string

P698

23412078

http://www.w3.org/2001/XMLSchema#string

P921

canagliflozin hemihydrate

P932

3714520

http://www.w3.org/2001/XMLSchema#string